Last data update: Apr 29, 2024. (Total: 46658 publications since 2009)
Records 1-3 (of 3 Records) |
Query Trace: Matheny AM [original query] |
---|
High-contact object and surface contamination in a household of persons with Monkeypox Virus Infection - Utah, June 2022
Pfeiffer JA , Collingwood A , Rider LE , Minhaj FS , Matheny AM , Kling C , McCollum AM , Nolen LD , Morgan CN . MMWR Morb Mortal Wkly Rep 2022 71 (34) 1092-1094 In May 2022, the Salt Lake County Health Department reported two real-time polymerase chain reaction (PCR)-confirmed travel-associated cases of monkeypox to the Utah Department of Health and Human Services (UDHHS). The two persons with monkeypox (patients A and B) lived together without other housemates. Both persons experienced prodromal symptoms (e.g., fatigue and body aches). Eight days after symptom onset, patient A experienced penile lesions; lesions spread to the lips, hands, legs, chest, and scalp by day 10. Patient B experienced prodromal symptoms 8 days after illness onset of patient A; patient B experienced a lesion on the foot which spread to the leg and finger by day 11. Although both patients had lesions in multiple anatomic areas, the overall number of lesions was small, and lesions varied in presentation from "pimple-like" or ulcerated, to characteristically well-circumscribed and centrally umbilicated. Both patients had mild illness. The time from symptom onset to resolution was approximately 30 days for patient A and approximately 22 days for patient B. |
Laboratory infection of novel Akhmeta virus in CAST/EiJ mice
Morgan CN , Matheny AM , Nakazawa YJ , Kling C , Gallardo-Romero N , Seigler L , Barbosa Costa G , Hutson C , Maghlakelidze G , Olson V , Doty JB . Viruses 2020 12 (12) Akhmeta virus is a zoonotic Orthopoxvirus first identified in 2013 in the country of Georgia. Subsequent ecological investigations in Georgia have found evidence that this virus is widespread in its geographic distribution within the country and in its host-range, with rodents likely involved in its circulation in the wild. Yet, little is known about the pathogenicity of this virus in rodents. We conducted the first laboratory infection of Akhmeta virus in CAST/EiJ Mus musculus to further characterize this novel virus. We found a dose-dependent effect on mortality and weight loss (p < 0.05). Anti-orthopoxvirus antibodies were detected in the second- and third-highest dose groups (5 × 10(4) pfu and 3 × 10(2) pfu) at euthanasia by day 10, and day 14 post-infection, respectively. Anti-orthopoxvirus antibodies were not detected in the highest dose group (3 × 10(6) pfu), which were euthanized at day 7 post-infection and had high viral load in tissues, suggesting they succumbed to disease prior to mounting an effective immune response. In order of highest burden, viable virus was detected in the nostril, lung, tail, liver and spleen. All individuals tested in the highest dose groups were DNAemic. Akhmeta virus was highly pathogenic in CAST/EiJ Mus musculus, causing 100% mortality when ≥3 × 10(2) pfu was administered. |
Pharmacokinetic profiles of gabapentin after oral and subcutaneous administration in black-tailed prairie dogs (Cynomys ludovicianus)
Mills PO , Tansey CO , Genzer SC , Mauldin MR , Howard RA , Kling CA , Jackson FR , Matheny AM , Boothe DM , Lathrop GW , Powell N , Gallardo-Romero N . J Am Assoc Lab Anim Sci 2020 59 (3) 305-309 In veterinary and human medicine, gabapentin (a chemical analog of gamma-aminobutyric acid) is commonly prescribed to treat postoperative and chronic neuropathic pain. This study explored the pharmacokinetics of oral and subcutaneous administration of gabapentin at high (80 mg/kg) and low (30 mg/kg) doses as a potential analgesic in black-tailed prairie dogs (Cynomys ludovicianus; n = 24). The doses (30 and 80 mg/kg) and half maximal effective concentration (1.4 to 16.7 ng/mL) for this study were extrapolated from pharmacokinetic efficacy studies in rats, rabbits, and cats. Gabapentin in plasma was measured by using an immunoassay, and data were evaluated using noncompartmental analysis. The peak plasma concentrations (mean +/-1 SD) were 42.6 +/-14.8 and 115.5 +/-15.2 ng/mL, respectively, after 30 and 80 mg/kg SC and 14.5 +/-3.5 and 20.7 +/-6.1 ng/mL after the low and high oral dosages, respectively. All peak plasma concentrations of gabapentin occurred within 5 h of administration. Disappearance half-lives for the low and high oral doses were 7.4 +/- 6.0 h and 5.0 +/- 0.8 h, respectively. The results of this study demonstrate that oral administration of gabapentin at low (30 mg/kg) doses likely would achieve and maintain plasma concentrations at half maximum effective concentration for 12 h, making it a viable option for an every 12-h treatment. |
- Page last reviewed:Feb 1, 2024
- Page last updated:Apr 29, 2024
- Content source:
- Powered by CDC PHGKB Infrastructure